{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T02:53:03Z","timestamp":1794451983915,"version":"4.9.1"},"reference-count":170,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41571-025-01099-7","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T11:48:39Z","timestamp":1764935319000},"page":"107-120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["The global epidemiology of acute myeloid leukaemia"],"prefix":"10.1038","volume":"23","author":[{"given":"Firas","family":"El Chaer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-0902","authenticated-orcid":false,"given":"Jan P.","family":"Bewersdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"1099_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury, J. D. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36, 1703\u20131719 (2022).","journal-title":"Leukemia"},{"key":"1099_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1329529","volume":"11","author":"P Chen","year":"2023","unstructured":"Chen, P. et al. Global, national, and regional burden of acute myeloid leukemia among 60-89 years-old individuals: insights from a study covering the period 1990 to 2019. Front. Public Health 11, 1329529 (2023).","journal-title":"Front. Public Health"},{"key":"1099_CR3","first-page":"2813","volume":"141","author":"F El Chaer","year":"2023","unstructured":"El Chaer, F., Hourigan, C. S. & Zeidan, A. M. How I treat AML incorporating the updated classifications and guidelines. Blood 141, 2813\u20132823 (2023).","journal-title":"Blood"},{"key":"1099_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-00987-8","volume":"22","author":"LA Meillon-Garcia","year":"2020","unstructured":"Meillon-Garcia, L. A. & Demichelis-G\u00f3mez, R. Access to therapy for acute myeloid leukemia in the developing world: barriers and solutions. Curr. Oncol. Rep. 22, 125 (2020).","journal-title":"Curr. Oncol. Rep."},{"key":"1099_CR5","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"1099_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00649-y","volume":"12","author":"Y Zhou","year":"2024","unstructured":"Zhou, Y. et al. Global, regional, and national burden of acute myeloid leukemia, 1990-2021: a systematic analysis for the Global Burden of Disease study 2021. Biomark. Res. 12, 101 (2024).","journal-title":"Biomark. Res."},{"key":"1099_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13045-020-00908-z","volume":"13","author":"M Yi","year":"2020","unstructured":"Yi, M. et al. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the Global Burden of Disease study 2017. J. Hematol. Oncol. 13, 72 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"1099_CR8","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","volume":"403","author":"GBD 2021 Causes of Death Collaborators.","year":"2024","unstructured":"GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease study 2021. Lancet 403, 2100\u20132132 (2024).","journal-title":"Lancet"},{"key":"1099_CR9","unstructured":"Cancer Research UK. Acute Myeloid Leukaemia (AML) Incidence Statistics https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/leukaemia-aml\/incidence#heading-Three (2025)."},{"key":"1099_CR10","unstructured":"National Cancer Institute \u2014 Surveillance, Epidemiology, and End Results Program. Cancer Statistics Explorer Network https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=96&data_type=1&graph_type=1&compareBy=sex&chk_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=1&advopt_precision=1&advopt_show_ci=on&hdn_view=1&advopt_show_apc=on&advopt_display=1#resultsRegion1 (2025)."},{"key":"1099_CR11","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman, J. W. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114, 937\u2013951 (2009).","journal-title":"Blood"},{"key":"1099_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_432218","volume":"44","author":"LA Godley","year":"2024","unstructured":"Godley, L. A., DiNardo, C. D. & Bolton, K. Germline predisposition in hematologic malignancies: testing, management, and implications. Am. Soc. Clin. Oncol. Educ. Book 44, e432218 (2024).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"1099_CR13","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1182\/blood.2022015790","volume":"140","author":"SK Feurstein","year":"2022","unstructured":"Feurstein, S. K. et al. Germline predisposition variants occur in myelodysplastic syndrome patients of all ages. Blood 140, 2533\u20132548 (2022).","journal-title":"Blood"},{"key":"1099_CR14","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1038\/s41375-021-01137-0","volume":"35","author":"S Feurstein","year":"2021","unstructured":"Feurstein, S. et al. Germline variants drive myelodysplastic syndrome in young adults. Leukemia 35, 2439\u20132444 (2021).","journal-title":"Leukemia"},{"key":"1099_CR15","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in Adults: 2022 ELN recommendations from an international expert panel. Blood 140, 1345\u20131377 (2022).","journal-title":"Blood"},{"key":"1099_CR16","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1182\/blood.2022018221","volume":"141","author":"H Makishima","year":"2023","unstructured":"Makishima, H. et al. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood 141, 534\u2013549 (2023).","journal-title":"Blood"},{"key":"1099_CR17","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1182\/blood.2023020209","volume":"142","author":"S Cheloor Kovilakam","year":"2023","unstructured":"Cheloor Kovilakam, S. et al. Prevalence and significance of DDX41 gene variants in the general population. Blood 142, 1185\u20131192 (2023).","journal-title":"Blood"},{"key":"1099_CR18","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1182\/bloodadvances.2022008172","volume":"7","author":"C Saygin","year":"2023","unstructured":"Saygin, C. et al. Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Adv. 7, 549\u2013554 (2023).","journal-title":"Blood Adv."},{"key":"1099_CR19","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2016.310","volume":"31","author":"G Berger","year":"2017","unstructured":"Berger, G. et al. Re-emergence of acute myeloid leukemia in donor cells following allogeneic transplantation in a family with a germline DDX41 mutation. Leukemia 31, 520\u2013522 (2017).","journal-title":"Leukemia"},{"key":"1099_CR20","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1080\/10428194.2023.2220457","volume":"64","author":"A Hamidi","year":"2023","unstructured":"Hamidi, A. et al. Clinical guideline variability in the diagnosis of hereditary hematopoietic malignancy syndromes. Leuk. Lymphoma 64, 1562\u20131565 (2023).","journal-title":"Leuk. Lymphoma"},{"key":"1099_CR21","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1182\/blood-2018-01-827881","volume":"131","author":"E Padron","year":"2018","unstructured":"Padron, E. et al. Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes. Blood 131, 2402\u20132405 (2018).","journal-title":"Blood"},{"key":"1099_CR22","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.3324\/haematol.2024.285054","volume":"109","author":"M Krystel-Whittemore","year":"2024","unstructured":"Krystel-Whittemore, M. et al. Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies. Haematologica 109, 3269\u20133281 (2024).","journal-title":"Haematologica"},{"key":"1099_CR23","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.3324\/haematol.2024.285055","volume":"109","author":"O Ceyhan-Birsoy","year":"2024","unstructured":"Ceyhan-Birsoy, O. et al. Universal germline genetic testing in patients with hematologic malignancies using DNA isolated from nail clippings. Haematologica 109, 3383\u20133390 (2024).","journal-title":"Haematologica"},{"key":"1099_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133265","volume":"15","author":"A Kosmidou","year":"2023","unstructured":"Kosmidou, A., Tragiannidis, A. & Gavriilaki, E. Myeloid leukemia of Down syndrome. Cancers 15, 3265 (2023).","journal-title":"Cancers"},{"key":"1099_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.891214","volume":"13","author":"J Li","year":"2022","unstructured":"Li, J. & Kalev-Zylinska, M. L. Advances in molecular characterization of myeloid proliferations associated with Down syndrome. Front. Genet. 13, 891214 (2022).","journal-title":"Front. Genet."},{"key":"1099_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis, R. M., Wang, R., Davidoff, A., Ma, X. & Zeidan, A. M. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 36, 70\u201387 (2019).","journal-title":"Blood Rev."},{"key":"1099_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph21080981","volume":"21","author":"K Samsel","year":"2024","unstructured":"Samsel, K. et al. Leukemia incidence by occupation and industry: a cohort study of 2.3 million workers from Ontario, Canada. Int. J. Environ. Res. Public Health 21, 981 (2024).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"1099_CR28","first-page":"457","volume":"18","author":"G Van Maele-Fabry","year":"2007","unstructured":"Van Maele-Fabry, G., Duhayon, S. & Lison, D. A systematic review of myeloid leukemias and occupational pesticide exposure. Cancer Causes Control. 18, 457\u2013478 (2007).","journal-title":"Cancer Causes Control."},{"key":"1099_CR29","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.3109\/10428194.2014.894189","volume":"55","author":"RJ Tsai","year":"2014","unstructured":"Tsai, R. J. et al. Acute myeloid leukemia risk by industry and occupation. Leuk. Lymphoma 55, 2584\u20132591 (2014).","journal-title":"Leuk. Lymphoma"},{"key":"1099_CR30","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1056\/NEJM196410222711703","volume":"271","author":"EC Vigliani","year":"1964","unstructured":"Vigliani, E. C. & Saita, G. Benzene and leukemia. N. Engl. J. Med. 271, 872\u2013876 (1964).","journal-title":"N. Engl. J. Med."},{"key":"1099_CR31","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/S1470-2045(17)30832-X","volume":"18","author":"D Loomis","year":"2017","unstructured":"Loomis, D. et al. Carcinogenicity of benzene. Lancet Oncol. 18, 1574\u20131575 (2017).","journal-title":"Lancet Oncol."},{"key":"1099_CR32","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood.V44.6.837.837","volume":"44","author":"M Aksoy","year":"1974","unstructured":"Aksoy, M., Erdem, \u015e & Din\u00c7ol, G. Leukemia in shoe-workers exposed chronically to benzene. Blood 44, 837\u2013841 (1974).","journal-title":"Blood"},{"key":"1099_CR33","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/jnci\/djy143","volume":"111","author":"MS Linet","year":"2018","unstructured":"Linet, M. S. et al. Benzene exposure response and risk of myeloid neoplasms in Chinese workers: a multicenter case\u2013cohort study. J. Natl Cancer Inst. 111, 465\u2013474 (2018).","journal-title":"J. Natl Cancer Inst."},{"key":"1099_CR34","first-page":"1","volume":"289","author":"National Toxicology Program.","year":"1986","unstructured":"National Toxicology Program. NTP toxicology and carcinogenesis studies of benzene (CAS No. 71-43-2) in F344\/N rats and B6C3F1 mice (gavage studies). Natl Toxicol. Program Tech. Rep. Ser. 289, 1\u2013277 (1986).","journal-title":"Natl Toxicol. Program Tech. Rep. Ser."},{"key":"1099_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1289\/ehp.8982109","volume":"82","author":"C Maltoni","year":"1989","unstructured":"Maltoni, C., Ciliberti, A., Cotti, G., Conti, B. & Belpoggi, F. Benzene, an experimental multipotential carcinogen: results of the long-term bioassays performed at the Bologna institute of oncology. Env. Health Perspect. 82, 109\u2013124 (1989).","journal-title":"Env. Health Perspect."},{"key":"1099_CR36","doi-asserted-by":"publisher","first-page":"351","DOI":"10.5271\/sjweh.4164","volume":"50","author":"C Ge","year":"2024","unstructured":"Ge, C. et al. Occupational exposure to benzene and mortality risk of lymphohaematopoietic cancers in the Swiss national cohort. Scand. J. Work. Env. Health 50, 351\u2013358 (2024).","journal-title":"Scand. J. Work. Env. Health"},{"key":"1099_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2025.154061","volume":"511","author":"J Zhou","year":"2025","unstructured":"Zhou, J. et al. Benzene-induced hematotoxicity enhances the self-renewal ability of HSPCs in Mll-Af9 mice. Toxicology 511, 154061 (2025).","journal-title":"Toxicology"},{"key":"1099_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26031138","volume":"26","author":"S Vivarelli","year":"2025","unstructured":"Vivarelli, S., Sevim, C., Giamb\u00f2, F. & Fenga, C. Integrated computational analysis reveals early genetic and epigenetic AML susceptibility biomarkers in benzene-exposed workers. Int. J. Mol. Sci. 26, 1138 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"1099_CR39","doi-asserted-by":"publisher","first-page":"60927","DOI":"10.1007\/s11356-024-35304-4","volume":"31","author":"D Galatro","year":"2024","unstructured":"Galatro, D. et al. Considerations for using tree-based machine learning to assess causation between demographic and environmental risk factors and health outcomes. Env. Sci. Pollut. Res. Int. 31, 60927\u201360935 (2024).","journal-title":"Env. Sci. Pollut. Res. Int."},{"key":"1099_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55100638","volume":"55","author":"A Allegra","year":"2019","unstructured":"Allegra, A. et al. Formaldehyde exposure and acute myeloid leukemia: a review of the literature. Medicina 55, 638 (2019).","journal-title":"Medicina"},{"key":"1099_CR41","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/JOM.0000000000000466","volume":"57","author":"H Checkoway","year":"2015","unstructured":"Checkoway, H. et al. Formaldehyde exposure and mortality risks from acute myeloid leukemia and other lymphohematopoietic malignancies in the US National Cancer Institute cohort study of workers in formaldehyde industries. J. Occup. Env. Med. 57, 785\u2013794 (2015).","journal-title":"J. Occup. Env. Med."},{"key":"1099_CR42","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1080\/10408444.2024.2337435","volume":"54","author":"LA Cox Jr.","year":"2024","unstructured":"Cox, L. A. Jr., Thompson, W. J. & Mundt, K. A. Interventional probability of causation (IPoC) with epidemiological and partial mechanistic evidence: benzene vs. formaldehyde and acute myeloid leukemia (AML). Crit. Rev. Toxicol. 54, 252\u2013289 (2024).","journal-title":"Crit. Rev. Toxicol."},{"key":"1099_CR43","unstructured":"International Agency for Research on Cancer. IARC Monographs on the Identification of Carcinogenic Hazards to Humans. Agents Classified by the IARC Monographs, Volumes 1\u2013135 https:\/\/monographs.iarc.who.int\/agents-classified-by-the-iarc\/ (2025)."},{"key":"1099_CR44","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.canep.2015.12.005","volume":"40","author":"JN Poynter","year":"2016","unstructured":"Poynter, J. N. et al. Obesity over the life course and risk of acute myeloid leukemia and myelodysplastic syndromes. Cancer Epidemiol. 40, 134\u2013140 (2016).","journal-title":"Cancer Epidemiol."},{"key":"1099_CR45","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.leukres.2011.12.020","volume":"36","author":"JJ Castillo","year":"2012","unstructured":"Castillo, J. J. et al. Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies. Leuk. Res. 36, 868\u2013875 (2012).","journal-title":"Leuk. Res."},{"key":"1099_CR46","first-page":"331","volume":"28","author":"O Shamriz","year":"2017","unstructured":"Shamriz, O. et al. Higher body mass index in 16-19 year-old Jewish adolescents of North African, Middle Eastern and European origins is a predictor of acute myeloid leukemia: a cohort of 2.3 million Israelis. Cancer Causes Control. 28, 331\u2013339 (2017).","journal-title":"Cancer Causes Control."},{"key":"1099_CR47","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1002\/cncr.34807","volume":"129","author":"JM Foran","year":"2023","unstructured":"Foran, J. M. et al. Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: an ECOG-ACRIN analysis. Cancer 129, 2479\u20132490 (2023).","journal-title":"Cancer"},{"key":"1099_CR48","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1001\/jama.293.2.203","volume":"293","author":"BJ Lange","year":"2005","unstructured":"Lange, B. J. et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA 293, 203\u2013211 (2005).","journal-title":"JAMA"},{"key":"1099_CR49","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1002\/cncr.27640","volume":"118","author":"H Inaba","year":"2012","unstructured":"Inaba, H. et al. Effect of body mass index on the outcome of children with acute myeloid leukemia. Cancer 118, 5989\u20135996 (2012).","journal-title":"Cancer"},{"key":"1099_CR50","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.3324\/haematol.2011.056390","volume":"97","author":"BC Medeiros","year":"2012","unstructured":"Medeiros, B. C., Othus, M., Estey, E. H., Fang, M. & Appelbaum, F. R. Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. Haematologica 97, 1401\u20131404 (2012).","journal-title":"Haematologica"},{"key":"1099_CR51","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/ajh.23530","volume":"88","author":"CM Wenzell","year":"2013","unstructured":"Wenzell, C. M. et al. Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight. Am. J. Hematol. 88, 906\u2013909 (2013).","journal-title":"Am. J. Hematol."},{"key":"1099_CR52","doi-asserted-by":"publisher","first-page":"E125","DOI":"10.1002\/ajh.23744","volume":"89","author":"S Fircanis","year":"2014","unstructured":"Fircanis, S., Merriam, P., Khan, N. & Castillo, J. J. The relation between cigarette smoking and risk of acute myeloid leukemia: an updated meta-analysis of epidemiological studies. Am. J. Hematol. 89, E125\u2013E132 (2014).","journal-title":"Am. J. Hematol."},{"key":"1099_CR53","doi-asserted-by":"publisher","first-page":"5702","DOI":"10.1182\/blood-2023-185349","volume":"142","author":"S Alqahtani","year":"2023","unstructured":"Alqahtani, S., Figueroa, M., Ma, H. & Chandra, J. Investigating the impact of smoking traditional and E-cigarettes on acute myeloid leukemia progression. Blood 142, 5702 (2023).","journal-title":"Blood"},{"key":"1099_CR54","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1111\/risa.12956","volume":"38","author":"S Fiebelkorn","year":"2018","unstructured":"Fiebelkorn, S. & Meredith, C. Estimation of the leukemia risk in human populations exposed to benzene from tobacco smoke using epidemiological data. Risk Anal. 38, 1490\u20131501 (2018).","journal-title":"Risk Anal."},{"key":"1099_CR55","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","volume":"52","author":"KL Bolton","year":"2020","unstructured":"Bolton, K. L. et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat. Genet. 52, 1219\u20131226 (2020).","journal-title":"Nat. Genet."},{"key":"1099_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-09604-z","volume":"12","author":"MG Levin","year":"2022","unstructured":"Levin, M. G. et al. Genetics of smoking and risk of clonal hematopoiesis. Sci. Rep. 12, 7248 (2022).","journal-title":"Sci. Rep."},{"key":"1099_CR57","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.canep.2014.06.001","volume":"38","author":"M Rota","year":"2014","unstructured":"Rota, M. et al. Alcohol drinking and risk of leukemia \u2014 a systematic review and meta-analysis of the dose\u2013risk relation. Cancer Epidemiol. 38, 339\u2013345 (2014).","journal-title":"Cancer Epidemiol."},{"key":"1099_CR58","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.leukres.2006.07.002","volume":"31","author":"G Gorini","year":"2007","unstructured":"Gorini, G. et al. Alcohol consumption and risk of leukemia: a multicenter case\u2013control study. Leuk. Res. 31, 379\u2013386 (2007).","journal-title":"Leuk. Res."},{"key":"1099_CR59","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc.2017.60","volume":"17","author":"ME McNerney","year":"2017","unstructured":"McNerney, M. E., Godley, L. A. & Le Beau, M. M. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat. Rev. Cancer 17, 513\u2013527 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"1099_CR60","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber, D. A. et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: integrating morphological, clinical, and genomic data. Blood 140, 1200\u20131228 (2022).","journal-title":"Blood"},{"key":"1099_CR61","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature13968","volume":"518","author":"TN Wong","year":"2015","unstructured":"Wong, T. N. et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518, 552\u2013555 (2015).","journal-title":"Nature"},{"key":"1099_CR62","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1182\/blood-2018-99-119530","volume":"132","author":"K Bolton","year":"2018","unstructured":"Bolton, K. et al. Oncologic therapy for solid tumors alters the risk of clonal hematopoiesis. Blood 132, 747 (2018).","journal-title":"Blood"},{"key":"1099_CR63","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","volume":"21","author":"CC Coombs","year":"2017","unstructured":"Coombs, C. C. et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 21, 374\u201382.e4 (2017).","journal-title":"Cell Stem Cell"},{"key":"1099_CR64","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41586-018-0125-z","volume":"557","author":"M Meisel","year":"2018","unstructured":"Meisel, M. et al. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557, 580\u2013584 (2018).","journal-title":"Nature"},{"issue":"Suppl. 1","key":"1099_CR65","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.1001\/dmp.2011.21","volume":"5","author":"EB Douple","year":"2011","unstructured":"Douple, E. B. et al. Long-term radiation-related health effects in a unique human population: lessons learned from the atomic bomb survivors of Hiroshima and Nagasaki. Disaster Med. Public Health Prep. 5 (Suppl. 1), S122\u2013S133 (2011).","journal-title":"Disaster Med. Public Health Prep."},{"key":"1099_CR66","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1667\/RR1231.1","volume":"170","author":"A Kesminiene","year":"2008","unstructured":"Kesminiene, A. et al. Risk of hematological malignancies among chernobyl liquidators. Radiat. Res. 170, 721\u2013735 (2008).","journal-title":"Radiat. Res."},{"key":"1099_CR67","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/ijc.10811","volume":"103","author":"AK Mohan","year":"2003","unstructured":"Mohan, A. K. et al. Cancer and other causes of mortality among radiologic technologists in the United States. Int. J. Cancer 103, 259\u2013267 (2003).","journal-title":"Int. J. Cancer"},{"key":"1099_CR68","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jama.2022.14578","volume":"328","author":"MA Sekeres","year":"2022","unstructured":"Sekeres, M. A. & Taylor, J. Diagnosis and treatment of myelodysplastic syndromes: a review. JAMA 328, 872\u2013880 (2022).","journal-title":"JAMA"},{"key":"1099_CR69","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1182\/blood.2023020817","volume":"143","author":"T Hall","year":"2024","unstructured":"Hall, T., Gurbuxani, S. & Crispino, J. D. Malignant progression of preleukemic disorders. Blood 143, 2245\u20132255 (2024).","journal-title":"Blood"},{"key":"1099_CR70","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"RC Lindsley","year":"2015","unstructured":"Lindsley, R. C. et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 125, 1367\u20131376 (2015).","journal-title":"Blood"},{"key":"1099_CR71","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/leu.2017.17","volume":"31","author":"T Kim","year":"2017","unstructured":"Kim, T. et al. The clonal origins of leukemic progression of myelodysplasia. Leukemia 31, 1928\u20131935 (2017).","journal-title":"Leukemia"},{"key":"1099_CR72","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/ng.3742","volume":"49","author":"H Makishima","year":"2017","unstructured":"Makishima, H. et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat. Genet. 49, 204\u2013212 (2017).","journal-title":"Nat. Genet."},{"key":"1099_CR73","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41591-018-0267-4","volume":"25","author":"J Chen","year":"2019","unstructured":"Chen, J. et al. Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. Nat. Med. 25, 103\u2013110 (2019).","journal-title":"Nat. Med."},{"key":"1099_CR74","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature10738","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506\u2013510 (2012).","journal-title":"Nature"},{"key":"1099_CR75","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi, A. et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 124, 2507\u20132513 (2014).","journal-title":"Blood"},{"key":"1099_CR76","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1182\/hematology.2022000341","volume":"2022","author":"JP Bewersdorf","year":"2022","unstructured":"Bewersdorf, J. P. & Rampal, R. K. Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts. Hematology Am. Soc. Hematol. Educ. Program 2022, 218\u2013224 (2022).","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"1099_CR77","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi, A. et al. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia 32, 1200\u20131210 (2018).","journal-title":"Leukemia"},{"key":"1099_CR78","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/hon.2737","volume":"38","author":"F Palandri","year":"2020","unstructured":"Palandri, F. et al. Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: real-world data. Hematol. Oncol. 38, 372\u2013380 (2020).","journal-title":"Hematol. Oncol."},{"key":"1099_CR79","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi, A. et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27, 1874\u20131881 (2013).","journal-title":"Leukemia"},{"issue":"4 Pt 2","key":"1099_CR80","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1055\/s-2006-942762","volume":"32","author":"JJ Kiladjian","year":"2006","unstructured":"Kiladjian, J. J. et al. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin. Thromb. Hemost. 32(4 Pt 2), 417\u2013421 (2006).","journal-title":"Semin. Thromb. Hemost."},{"key":"1099_CR81","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","volume":"29","author":"M Bj\u00f6rkholm","year":"2011","unstructured":"Bj\u00f6rkholm, M. et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J. Clin. Oncol. 29, 2410\u20132415 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1099_CR82","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa1412098","volume":"372","author":"CA Ortmann","year":"2015","unstructured":"Ortmann, C. A. et al. Effect of mutation order on myeloproliferative neoplasms. N. Engl. J. Med. 372, 601\u2013612 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1099_CR83","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","volume":"587","author":"LA Miles","year":"2020","unstructured":"Miles, L. A. et al. Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature 587, 477\u2013482 (2020).","journal-title":"Nature"},{"key":"1099_CR84","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1182\/bloodadvances.2018015875","volume":"2","author":"TL Lasho","year":"2018","unstructured":"Lasho, T. L. et al. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. Blood Adv. 2, 370\u2013380 (2018).","journal-title":"Blood Adv."},{"key":"1099_CR85","doi-asserted-by":"publisher","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","volume":"111","author":"R Rampal","year":"2014","unstructured":"Rampal, R. et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc. Natl Acad. Sci. USA 111, E5401\u2013E5410 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1099_CR86","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","volume":"123","author":"P Lundberg","year":"2014","unstructured":"Lundberg, P. et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 123, 2220\u20132228 (2014).","journal-title":"Blood"},{"key":"1099_CR87","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s41588-023-01480-1","volume":"55","author":"A Rodriguez-Meira","year":"2023","unstructured":"Rodriguez-Meira, A. et al. Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution. Nat. Genet. 55, 1531\u20131541 (2023).","journal-title":"Nat. Genet."},{"key":"1099_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100711","author":"S Koschmieder","year":"2020","unstructured":"Koschmieder, S. & Chatain, N. Role of inflammation in the biology of myeloproliferative neoplasms. Blood Rev. https:\/\/doi.org\/10.1016\/j.blre.2020.100711 (2020).","journal-title":"Blood Rev."},{"key":"1099_CR89","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1182\/blood.2019000940","volume":"136","author":"L Sun","year":"2020","unstructured":"Sun, L. & Babushok, D. V. Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria. Blood 136, 36\u201349 (2020).","journal-title":"Blood"},{"key":"1099_CR90","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMra1413485","volume":"379","author":"NS Young","year":"2018","unstructured":"Young, N. S. Aplastic anemia. N. Engl. J. Med. 379, 1643\u20131656 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1099_CR91","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1414799","volume":"373","author":"T Yoshizato","year":"2015","unstructured":"Yoshizato, T. et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N. Engl. J. Med. 373, 35\u201347 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1099_CR92","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/bjh.14691","volume":"178","author":"HS Park","year":"2017","unstructured":"Park, H. S. et al. Telomere length and somatic mutations in correlation with response to immunosuppressive treatment in aplastic anaemia. Br. J. Haematol. 178, 603\u2013615 (2017).","journal-title":"Br. J. Haematol."},{"key":"1099_CR93","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1182\/blood-2014-10-607572","volume":"125","author":"B Dumitriu","year":"2015","unstructured":"Dumitriu, B. et al. Telomere attrition and candidate gene mutations preceding monosomy 7 in aplastic anemia. Blood 125, 706\u2013709 (2015).","journal-title":"Blood"},{"key":"1099_CR94","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1182\/blood.V99.9.3129","volume":"99","author":"JP Maciejewski","year":"2002","unstructured":"Maciejewski, J. P., Risitano, A., Sloand, E. M., Nunez, O. & Young, N. S. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 99, 3129\u20133135 (2002).","journal-title":"Blood"},{"key":"1099_CR95","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.3324\/haematol.2018.206540","volume":"104","author":"ZR Rogers","year":"2019","unstructured":"Rogers, Z. R. et al. Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study. Haematologica 104, 1974\u20131983 (2019).","journal-title":"Haematologica"},{"key":"1099_CR96","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1182\/blood-2008-01-133918","volume":"112","author":"RP de Latour","year":"2008","unstructured":"de Latour, R. P. et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood 112, 3099\u20133106 (2008).","journal-title":"Blood"},{"key":"1099_CR97","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","volume":"126","author":"DP Steensma","year":"2015","unstructured":"Steensma, D. P. et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126, 9\u201316 (2015).","journal-title":"Blood"},{"key":"1099_CR98","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal, S. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med. 377, 111\u2013121 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1099_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12484","volume":"7","author":"AL Young","year":"2016","unstructured":"Young, A. L., Challen, G. A., Birmann, B. M. & Druley, T. E. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat. Commun. 7, 12484 (2016).","journal-title":"Nat. Commun."},{"key":"1099_CR100","doi-asserted-by":"publisher","first-page":"EVIDoa2200310","DOI":"10.1056\/EVIDoa2200310","volume":"2","author":"LD Weeks","year":"2023","unstructured":"Weeks, L. D. et al. Prediction of risk for myeloid malignancy in clonal hematopoiesis. NEJM Evid. 2, EVIDoa2200310 (2023).","journal-title":"NEJM Evid."},{"key":"1099_CR101","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","volume":"119","author":"GM Dores","year":"2012","unstructured":"Dores, G. M., Devesa, S. S., Curtis, R. E., Linet, M. S. & Morton, L. M. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 119, 34\u201343 (2012).","journal-title":"Blood"},{"key":"1099_CR102","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000356794","volume":"132","author":"JC Jaime-P\u00e9rez","year":"2014","unstructured":"Jaime-P\u00e9rez, J. C. et al. Characteristics and clinical evolution of patients with acute myeloblastic leukemia in northeast Mexico: an eight-year experience at a university hospital. Acta Haematol. 132, 144\u2013151 (2014).","journal-title":"Acta Haematol."},{"key":"1099_CR103","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000491989","volume":"140","author":"PR Colunga-Pedraza","year":"2018","unstructured":"Colunga-Pedraza, P. R., Gomez-Cruz, G. B., Colunga-Pedraza, J. E. & Ruiz-Arg\u00fcelles, G. J. Geographic hematology: some observations in Mexico. Acta Haematol. 140, 114\u2013120 (2018).","journal-title":"Acta Haematol."},{"key":"1099_CR104","doi-asserted-by":"publisher","first-page":"26","DOI":"10.59566\/IJBS.2013.9026","volume":"9","author":"CY Meng","year":"2013","unstructured":"Meng, C. Y., Noor, P. J., Ismail, A., Ahid, M. F. & Zakaria, Z. Cytogenetic profile of de novo acute myeloid leukemia patients in Malaysia. Int. J. Biomed. Sci. 9, 26\u201332 (2013).","journal-title":"Int. J. Biomed. Sci."},{"key":"1099_CR105","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/ajco.12333","volume":"11","author":"A Bahl","year":"2015","unstructured":"Bahl, A. et al. Long-term outcomes for patients with acute myeloid leukemia: a single-center experience from AIIMS, India. Asia Pac. J. Clin. Oncol. 11, 242\u2013252 (2015).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"1099_CR106","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","volume":"113","author":"G Juliusson","year":"2009","unstructured":"Juliusson, G. et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry. Blood 113, 4179\u20134187 (2009).","journal-title":"Blood"},{"key":"1099_CR107","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1159\/000524641","volume":"31","author":"SH Alshemmari","year":"2022","unstructured":"Alshemmari, S. H., Almazyad, M., Ram, M., John, L. M. & Alhuraiji, A. Epidemiology of de novo acute myeloid leukemia in kuwait per the 2016 WHO classification. Med. Princ. Pract. 31, 284\u2013292 (2022).","journal-title":"Med. Princ. Pract."},{"key":"1099_CR108","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jfma.2022.10.007","volume":"122","author":"L-N Chien","year":"2023","unstructured":"Chien, L.-N. et al. Epidemiology and survival outcomes of acute myeloid leukemia patients in Taiwan: a national population-based analysis from 2001 to 2015. J. Formos. Med. Assoc. 122, 505\u2013513 (2023).","journal-title":"J. Formos. Med. Assoc."},{"key":"1099_CR109","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1038\/s41375-024-02435-z","volume":"38","author":"JM Tettero","year":"2024","unstructured":"Tettero, J. M., Cloos, J. & Bullinger, L. Acute myeloid leukemia: does sex matter? Leukemia 38, 2329\u20132331 (2024).","journal-title":"Leukemia"},{"key":"1099_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092256","volume":"13","author":"CK Tebbi","year":"2021","unstructured":"Tebbi, C. K. Etiology of acute leukemia: a review. Cancers 13, 2256 (2021).","journal-title":"Cancers"},{"key":"1099_CR111","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41375-020-0935-5","volume":"35","author":"A De-Morgan","year":"2021","unstructured":"De-Morgan, A., Meggendorfer, M., Haferlach, C. & Shlush, L. Male predominance in AML is associated with specific preleukemic mutations. Leukemia 35, 867\u2013870 (2021).","journal-title":"Leukemia"},{"key":"1099_CR112","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1182\/blood.V87.1.308.308","volume":"87","author":"D Douer","year":"1996","unstructured":"Douer, D. et al. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood 87, 308\u2013313 (1996).","journal-title":"Blood"},{"key":"1099_CR113","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.leukres.2014.04.001","volume":"38","author":"AM Brunner","year":"2014","unstructured":"Brunner, A. M. et al. Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis. Leuk. Res. 38, 773\u2013780 (2014).","journal-title":"Leuk. Res."},{"key":"1099_CR114","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1182\/bloodadvances.2024014127","volume":"9","author":"X Wang","year":"2025","unstructured":"Wang, X. et al. Evolving racial\/ethnic disparities in AML survival in the novel therapy era. Blood Adv. 9, 533\u2013544 (2025).","journal-title":"Blood Adv."},{"key":"1099_CR115","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.1182\/bloodadvances.2024013102","volume":"8","author":"H Liu","year":"2024","unstructured":"Liu, H. et al. Impact of patient demographics on treatment outcomes in AML: a population-based registry in England, 2013-2020. Blood Adv. 8, 4593\u20134605 (2024).","journal-title":"Blood Adv."},{"key":"1099_CR116","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1158\/2159-8290.CD-20-1579","volume":"11","author":"B Bhatnagar","year":"2021","unstructured":"Bhatnagar, B. et al. Poor survival and differential impact of genetic features of black patients with acute myeloid leukemia. Cancer Discov. 11, 626\u2013637 (2021).","journal-title":"Cancer Discov."},{"key":"1099_CR117","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1182\/bloodadvances.2021005148","volume":"5","author":"A Hantel","year":"2021","unstructured":"Hantel, A. et al. Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials. Blood Adv. 5, 4352\u20134360 (2021).","journal-title":"Blood Adv."},{"key":"1099_CR118","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/s41375-024-02172-3","volume":"38","author":"DJ Olivieri","year":"2024","unstructured":"Olivieri, D. J. et al. Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Leukemia 38, 865\u2013876 (2024).","journal-title":"Leukemia"},{"key":"1099_CR119","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.1112","volume":"7","author":"LH Nielsen","year":"2024","unstructured":"Nielsen, L. H. et al. Socioeconomic status and overall survival among patients with hematological malignant neoplasms. JAMA Netw. Open 7, e241112 (2024).","journal-title":"JAMA Netw. Open"},{"key":"1099_CR120","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3324\/haematol.2024.286477","volume":"110","author":"CL Meyer","year":"2025","unstructured":"Meyer, C. L. et al. Utilization of allogeneic hematopoietic stem cell transplantation among patients with newly diagnosed acute myeloid leukemia in California: a population-based linked dataset study. Haematologica 110, 368\u2013377 (2025).","journal-title":"Haematologica"},{"key":"1099_CR121","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/ajh.24767","volume":"92","author":"VR Bhatt","year":"2017","unstructured":"Bhatt, V. R. et al. Early mortality and overall survival of acute myeloid leukemia based on facility type. Am. J. Hematol. 92, 764\u2013771 (2017).","journal-title":"Am. J. Hematol."},{"key":"1099_CR122","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1002\/cncr.31296","volume":"124","author":"G Ho","year":"2018","unstructured":"Ho, G. et al. Decreased early mortality associated with the treatment of acute myeloid leukemia at national cancer institute-designated cancer centers in California. Cancer 124, 1938\u20131945 (2018).","journal-title":"Cancer"},{"key":"1099_CR123","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.leukres.2011.10.018","volume":"36","author":"J Bierenbaum","year":"2012","unstructured":"Bierenbaum, J. et al. Racial differences in presentation, referral and treatment patterns and survival in adult patients with acute myeloid leukemia: a single-institution experience. Leuk. Res. 36, 140\u2013145 (2012).","journal-title":"Leuk. Res."},{"key":"1099_CR124","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.leukres.2015.02.003","volume":"39","author":"A Hahn","year":"2015","unstructured":"Hahn, A., Giri, S., Yaghmour, G. & Martin, M. G. Early mortality in acute myeloid leukemia. Leuk. Res. 39, 505\u2013509 (2015).","journal-title":"Leuk. Res."},{"key":"1099_CR125","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1182\/bloodadvances.2020001728","volume":"4","author":"AM Zeidan","year":"2020","unstructured":"Zeidan, A. M. et al. Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States. Blood Adv. 4, 1615\u20131623 (2020).","journal-title":"Blood Adv."},{"key":"1099_CR126","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.1016\/j.clml.2023.02.002","volume":"23","author":"A Gershon","year":"2023","unstructured":"Gershon, A. et al. Early real-world first-line treatment with venetoclax plus HMAs versus HMA monotherapy among patients with AML in a predominately US community setting. Clin. Lymphoma Myeloma Leuk. 23, e222\u2013e231 (2023).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"1099_CR127","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/oncolo\/oyac135","volume":"27","author":"P Vachhani","year":"2022","unstructured":"Vachhani, P. et al. Venetoclax and hypomethylating agents as first-line treatment in newly diagnosed patients with AML in a predominately community setting in the US. Oncologist 27, 907\u2013918 (2022).","journal-title":"Oncologist"},{"key":"1099_CR128","doi-asserted-by":"publisher","first-page":"e877","DOI":"10.1200\/OP.22.00822","volume":"19","author":"VR Bhatt","year":"2023","unstructured":"Bhatt, V. R. et al. Outcomes of older adults with AML treated in community versus academic centers: an analysis of alliance trials. JCO Oncol. Pract. 19, e877\u2013e891 (2023).","journal-title":"JCO Oncol. Pract."},{"key":"1099_CR129","doi-asserted-by":"publisher","first-page":"S337","DOI":"10.1016\/S2152-2650(24)01247-3","volume":"24","author":"D Patel","year":"2024","unstructured":"Patel, D. et al. Global burden and trends in acute myeloid leukemia in the European Union from 1990 to 2021: insights from the Global Burden of Disease study, 2021. Clin. Lymphoma Myeloma Leuk. 24, S337 (2024).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"1099_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100017","volume":"1","author":"J Othman","year":"2024","unstructured":"Othman, J. et al. Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS. Blood Neoplasia 1, 100017 (2024).","journal-title":"Blood Neoplasia"},{"key":"1099_CR131","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.leukres.2017.07.005","volume":"60","author":"MTL Benicio","year":"2017","unstructured":"Benicio, M. T. L. et al. Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle-income countries (LMIC): a Brazilian experience. Leuk. Res. 60, 109\u2013114 (2017).","journal-title":"Leuk. Res."},{"key":"1099_CR132","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/j.clml.2019.12.015","volume":"20","author":"R Demichelis-G\u00f3mez","year":"2020","unstructured":"Demichelis-G\u00f3mez, R. et al. Acute myeloid leukemia in Mexico: the specific challenges of a developing country. Results from a multicenter national registry. Clin. Lymphoma Myeloma Leuk. 20, e295\u2013e303 (2020).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"1099_CR133","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00277-019-03600-6","volume":"98","author":"GB Kanakasetty","year":"2019","unstructured":"Kanakasetty, G. B. et al. Treatment patterns and comparative analysis of non-intensive regimens in elderly acute myeloid leukemia patients \u2014 a real-world experience from India. Ann. Hematol. 98, 881\u2013888 (2019).","journal-title":"Ann. Hematol."},{"key":"1099_CR134","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10585-019-10003-4","volume":"36","author":"J Haier","year":"2019","unstructured":"Haier, J., Sleeman, J. & Sch\u00e4fers, J. Editorial series: cancer care in low- and middle-income countries. Clin. Exp. Metastasis 36, 477\u2013480 (2019).","journal-title":"Clin. Exp. Metastasis"},{"key":"1099_CR135","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40487-023-00229-4","volume":"11","author":"EE Gen\u00e7","year":"2023","unstructured":"Gen\u00e7, E. E., Sara\u00e7, \u0130., Arslan, H. & E\u015fkazan, A. E. Diagnostic and treatment obstacles in acute myeloid leukemia: social, operational, and financial. Oncol. Ther. 11, 145\u2013152 (2023).","journal-title":"Oncol. Ther."},{"key":"1099_CR136","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/bjh.13406","volume":"170","author":"C Philip","year":"2015","unstructured":"Philip, C. et al. Acute myeloid leukaemia: challenges and real world data from India. Br. J. Haematol. 170, 110\u2013117 (2015).","journal-title":"Br. J. Haematol."},{"key":"1099_CR137","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.clml.2018.02.002","volume":"18","author":"JC Jaime-P\u00e9rez","year":"2018","unstructured":"Jaime-P\u00e9rez, J. C. et al. Outcomes of adolescents and young adults with acute myeloid leukemia treated in a single Latin American center. Clin. Lymphoma Myeloma Leuk. 18, 286\u2013292 (2018).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"1099_CR138","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174760","volume":"12","author":"B Jabo","year":"2017","unstructured":"Jabo, B., Morgan, J. W., Martinez, M. E., Ghamsary, M. & Wieduwilt, M. J. Sociodemographic disparities in chemotherapy and hematopoietic cell transplantation utilization among adult acute lymphoblastic and acute myeloid leukemia patients. PLoS One 12, e0174760 (2017).","journal-title":"PLoS One"},{"key":"1099_CR139","first-page":"184.e1","volume":"27","author":"J Dehn","year":"2021","unstructured":"Dehn, J. et al. Likelihood of proceeding to allogeneic hematopoietic cell transplantation in the United States after search activation in the national registry: impact of patient age, disease, and search prognosis. Transpl. Cell Ther. 27, 184.e1\u2013e13 (2021).","journal-title":"Transpl. Cell Ther."},{"key":"1099_CR140","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1182\/bloodadvances.2018028662","volume":"3","author":"JN Barker","year":"2019","unstructured":"Barker, J. N. et al. Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis. Blood Adv. 3, 939\u2013944 (2019).","journal-title":"Blood Adv."},{"key":"1099_CR141","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/s41409-018-0164-y","volume":"53","author":"VR Bhatt","year":"2018","unstructured":"Bhatt, V. R., Chen, B., Gyawali, B. & Lee, S. J. Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia. Bone Marrow Transpl. 53, 1288\u20131294 (2018).","journal-title":"Bone Marrow Transpl."},{"key":"1099_CR142","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1016\/j.bbmt.2019.06.012","volume":"25","author":"K Paulson","year":"2019","unstructured":"Paulson, K. et al. Inferior access to allogeneic transplant in disadvantaged populations: a center for international blood and marrow transplant research analysis. Biol. Blood Marrow Transpl. 25, 2086\u20132090 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"1099_CR143","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/bmt.2015.246","volume":"51","author":"PL Delamater","year":"2016","unstructured":"Delamater, P. L. & Uberti, J. P. Geographic access to hematopoietic cell transplantation services in the United States. Bone Marrow Transpl. 51, 241\u2013248 (2016).","journal-title":"Bone Marrow Transpl."},{"key":"1099_CR144","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1182\/blood.2020006252","volume":"137","author":"K Bona","year":"2021","unstructured":"Bona, K. et al. Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. Blood 137, 556\u2013568 (2021).","journal-title":"Blood"},{"key":"1099_CR145","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/cncr.33232","volume":"127","author":"S Hong","year":"2021","unstructured":"Hong, S. et al. Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. Cancer 127, 609\u2013618 (2021).","journal-title":"Cancer"},{"key":"1099_CR146","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/s41409-019-0748-1","volume":"55","author":"NS Majhail","year":"2020","unstructured":"Majhail, N. S. et al. Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults. Bone Marrow Transpl. 55, 906\u2013917 (2020).","journal-title":"Bone Marrow Transpl."},{"key":"1099_CR147","first-page":"279.e1","volume":"29","author":"MC Tokaz","year":"2023","unstructured":"Tokaz, M. C. et al. An analysis of the worldwide utilization of hematopoietic stem cell transplantation for acute myeloid leukemia. Transpl. Cell Ther. 29, 279.e1\u2013e10 (2023).","journal-title":"Transpl. Cell Ther."},{"key":"1099_CR148","first-page":"485","volume":"57","author":"JW Yates","year":"1973","unstructured":"Yates, J. W., Wallace, H. J. Jr., Ellison, R. R. & Holland, J. F. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother. Rep. 57, 485\u2013488 (1973).","journal-title":"Cancer Chemother. Rep."},{"key":"1099_CR149","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3324\/haematol.2018.188888","volume":"104","author":"J Lambert","year":"2019","unstructured":"Lambert, J. et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica 104, 113\u2013119 (2019).","journal-title":"Haematologica"},{"key":"1099_CR150","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","volume":"34","author":"S Amadori","year":"2016","unstructured":"Amadori, S. et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 Trial. J. Clin. Oncol. 34, 972\u2013979 (2016).","journal-title":"J. Clin. Oncol."},{"key":"1099_CR151","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone, R. M. et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N. Engl. J. Med. 377, 454\u2013464 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1099_CR152","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein, E. M. et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130, 722\u2013731 (2017).","journal-title":"Blood"},{"key":"1099_CR153","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet, J. E. et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J. Clin. Oncol. 36, 2684\u20132692 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1099_CR154","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383, 617\u2013629 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1099_CR155","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei, A. H. et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135, 2137\u20132145 (2020).","journal-title":"Blood"},{"key":"1099_CR156","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo, C. D. et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N. Engl. J. Med. 378, 2386\u20132398 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1099_CR157","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl, A. E. et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-Mutated AML. N. Engl. J. Med. 381, 1728\u20131740 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1099_CR158","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos, P. et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N. Engl. J. Med. 386, 1519\u20131531 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1099_CR159","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","volume":"7","author":"S de Botton","year":"2023","unstructured":"de Botton, S. et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Adv. 7, 3117\u20133127 (2023).","journal-title":"Blood Adv."},{"key":"1099_CR160","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","volume":"383","author":"AH Wei","year":"2020","unstructured":"Wei, A. H. et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N. Engl. J. Med. 383, 2526\u20132537 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1099_CR161","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba, H. P. et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401, 1571\u20131583 (2023).","journal-title":"Lancet"},{"key":"1099_CR162","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.24.00826","volume":"43","author":"GC Issa","year":"2025","unstructured":"Issa, G. C. et al. Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J. Clin. Oncol. 43, 75\u201384 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1099_CR163","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1182\/blood.2024026232","volume":"145","author":"G Huls","year":"2025","unstructured":"Huls, G., Woolthuis, C. M. & Schuringa, J. J. Menin inhibitors in the treatment of acute myeloid leukemia. Blood 145, 561\u2013566 (2025).","journal-title":"Blood"},{"key":"1099_CR164","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","volume":"388","author":"GBD 2015 Mortality and Causes of Death Collaborators.","year":"2016","unstructured":"GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease study 2015. Lancet 388, 1459\u20131544 (2016).","journal-title":"Lancet"},{"key":"1099_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102549","volume":"71","author":"MS Linet","year":"2024","unstructured":"Linet, M. S. et al. Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001-2019. EClinicalMedicine 71, 102549 (2024).","journal-title":"EClinicalMedicine"},{"key":"1099_CR166","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/ijc.35516","volume":"157","author":"LJ Van Eycken","year":"2025","unstructured":"Van Eycken, L. J. et al. Future of population-based cancer registries: a global perspective \u2014 a survey of population-based cancer registries. Int. J. Cancer 157, 1566\u20131576 (2025).","journal-title":"Int. J. Cancer"},{"key":"1099_CR167","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293084","volume":"18","author":"V Anton-Vazquez","year":"2023","unstructured":"Anton-Vazquez, V. et al. Improving anaemia diagnosis using peripheral blood smear with remote interpretation in adults living with HIV with moderate to severe anaemia: a prospective study nested within the Kilombero and Ulanga antiretroviral cohort. PLoS One 18, e0293084 (2023).","journal-title":"PLoS One"},{"key":"1099_CR168","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.sapharm.2023.08.010","volume":"19","author":"OA Chukwu","year":"2023","unstructured":"Chukwu, O. A., Nnogo, C. C. & Essue, B. Task shifting to nonphysician health workers for improving access to care and treatment for cancer in low- and middle-income countries \u2014 a systematic review. Res. Soc. Adm. Pharm. 19, 1511\u20131519 (2023).","journal-title":"Res. Soc. Adm. Pharm."},{"issue":"Suppl. 1","key":"1099_CR169","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s13187-021-02031-0","volume":"36","author":"ML Varon","year":"2021","unstructured":"Varon, M. L. et al. Project ECHO cancer initiative: a tool to improve care and increase capacity along the continuum of cancer care. J. Cancer Educ. 36 (Suppl. 1), 25\u201338 (2021).","journal-title":"J. Cancer Educ."},{"key":"1099_CR170","doi-asserted-by":"publisher","DOI":"10.1200\/GO.23.00439","volume":"10","author":"OA Bamodu","year":"2024","unstructured":"Bamodu, O. A. & Chung, C. C. Cancer care disparities: overcoming barriers to cancer control in low- and middle-income countries. JCO Glob. Oncol. 10, e2300439 (2024).","journal-title":"JCO Glob. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01099-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01099-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01099-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T13:02:03Z","timestamp":1769518923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01099-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":170,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1099"],"URL":"https:\/\/doi.org\/10.1038\/s41571-025-01099-7","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"29 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.E.C. has acted as a consultant and\/or adviser of AbbVie, Amgen, the Association of Community Cancer Centers, Bristol Myers Squibb (BMS), CTI BioPharma, Daiichi Sankyo, DAVA Oncology, Geron, MorphoSys, Novartis, PharmaEssentia, Sobi, Sumitomo Pharma Oncology, Syndax and Taiho Oncology; he also received a travel grant from DAVA Oncology. M.S. has acted as a consultant and\/or adviser of Boston Consulting, BMS, Dedham group, GSK, GLG Insights, Kymera, Kura, Novartis, Rigel, Sierra Oncology, Sobi and Syndax; has participated in CME activity for Clinical Care Options, Curis Oncology, Haymarket Media and Novartis; and is a member of the Medical Safety Monitoring Board for Keros Pharmaceuticals. A.M.Z. has participated in advisory boards, consulted for, participated in clinical trial committees for and\/or received honoraria from AbbVie, Agios, Akesobio, Amgen, Astellas, Beigene, BioCryst, Boehringer-Ingelheim, Celgene\/BMS, Chiesi\/Cornerstone Biopharma, Daiichi Sankyo, Dr Reddy, Epizyme, Faron, Fibrogen, Genentech, Geron, Glycomimetics, Gilead, GSK, Janssen, Jasper, Karyopharm, Keros, Kura, Kyowa Kirin, Notable, Novartis, Orum, Otsuka, Pfizer, Regeneron, Rigel, Seattle Genetics, Shattuck Labs, Schrodinger, Syndax, Syros, Servier, Takeda, Treadwell, Taiho, Vincerx, and Zentalis. J.P.B. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}